INTEGRA LIFESCIENCES HOLDINGS CORP

Integra LifeSciences Holdings Corporation manufactures and sells medical technologies across two main business segments: Codman Specialty Surgical and Tissue Technologies. The specialty surgical segment supplies neurosurgical devices, neuro-monitoring systems, cranial stabilization equipment, ultrasonic tissue ablation tools, surgical headlamps, and specialty handheld instruments. The tissue technologies segment provides regenerative biomaterials, collagen implants, porcine matrices, human placental allografts, and dressings for wound management, plastic reconstruction, and general surgery. The company also produces private-label products for other medical firms. Its customers include hospitals, outpatient surgery centers, wound clinics, integrated health networks, and medical practices.

The enterprise markets products worldwide through direct sales representatives and independent distributors, serving markets in North America, Europe, and Asia, including China, Japan, South Korea, India, and Brazil. It maintains manufacturing and research facilities in eight U.S. states and Puerto Rico, as well as in France, Germany, Ireland, Israel, and Switzerland, plus an assembly site in Suzhou, China. The excerpt does not disclose the company's headquarters location.

Summary of the business section of Integra Lifesciences's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2020, we had approximately 3,700 full-time and part-time employees and 700 contingent, subcontracted and outsourced partners.”